Ana Carolina Soares Braga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Carolina Soares Braga has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alex Gregory Hamilton
Department of Bioengineering, University of Pennsylvania
1 shared publication - Alexander Birbrair
University of Wisconsin-Madison
1 shared publication Anderson Kenedy Santos
Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil
1 shared publicationAndréa Teixeira-Carvalho
Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil
1 shared publicationCelso Martins Queiroz-Junior
Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, Brazil
1 shared publicationFernanda Martins Marim
Department of Genetics, Federal University of Minas Gerais, Belo Horizonte, Brazil
1 shared publication
Latest Publications
- Open Access
- 18 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models
A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to provide safe and effective delivery of plasmid DNA (pDNA) and show protection against VOCs in female small animal models. Using a library of LNPs encapsulating unique barcoded DNA (b-DNA), we screen for b-DNA delivery after intramuscular administration. The top-performing LNPs are further tested for their capacity of pDNA uptake in antigen-presenting cells in vitro. The lead LNP is used to encapsulate pDNA encoding the HexaPro version of SARS-CoV-2 spike (LNP-HPS) and immunogenicity and protection is tested in vivo. LNP-HPS elicit a robust protective effect against SARS-CoV-2 Gamma (P.1), correlating with reduced lethality, decreased viral load in the lungs and reduced lung damage. LNP-HPS induce potent humoral and T cell responses against P.1, and generate high levels of neutralizing antibodies against P.1 and Omicron (B.1.1.529). Our findings indicate that the protective efficacy and immunogenicity elicited by LNP-HPS are comparable to those achieved by the approved COVID-19 vaccine from Biontech/Pfizer in animal models. Together, these findings suggest that LNP-HPS hold great promise as a vaccine candidate against VOCs.
- 18 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessNanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models
A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to provide safe and effective delivery of plasmid DNA (pDNA) and show protection against VOCs in female small animal models. Using a library of LNPs encapsulating unique barcoded DNA (b-DNA), we screen for b-DNA delivery after intramuscular administration. The top-performing LNPs are further tested for their capacity of pDNA uptake in antigen-presenting cells in vitro. The lead LNP is used to encapsulate pDNA encoding the HexaPro version of SARS-CoV-2 spike (LNP-HPS) and immunogenicity and protection is tested in vivo. LNP-HPS elicit a robust protective effect against SARS-CoV-2 Gamma (P.1), correlating with reduced lethality, decreased viral load in the lungs and reduced lung damage. LNP-HPS induce potent humoral and T cell responses against P.1, and generate high levels of neutralizing antibodies against P.1 and Omicron (B.1.1.529). Our findings indicate that the protective efficacy and immunogenicity elicited by LNP-HPS are comparable to those achieved by the approved COVID-19 vaccine from Biontech/Pfizer in animal models. Together, these findings suggest that LNP-HPS hold great promise as a vaccine candidate against VOCs.